KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors

Seiichi Hirota, Koji Isozaki, Y Moriyama et al. · Science · 1998 · 4.5K citations

Medicine, Genetics, Oncology +17

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · New England Journal of Medicine · 2002 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +14

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Brian Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine · 1996 · 3.7K citations

Life Sciences, Molecular Biology, Oncology +13

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich, Christopher L. Corless, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 2.3K citations

Medicine, Molecular Medicine, Oncology +17

Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors

Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 1.3K citations

Medicine, Oncology, Pharmacology +15